skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Nelipepimut-S Plus GM-CSF Vaccine (Code C99228)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Nelipepimut-S Plus GM-CSF Vaccine

Definition: A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response.

Display Name: Nelipepimut-S Plus GM-CSF Vaccine

Label: Nelipepimut-S Plus GM-CSF Vaccine

NCI Thesaurus Code: C99228 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL433057  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
E75 Plus GM-CSF
E75 Vaccine Plus GM-CSF
HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF
Nelipepimut-S Plus GM-CSF Vaccine
Nelipepimut-S Plus Sargramostim
NeuVax Plus GM-CSF

External Source Codes: 
PDQ Closed Trial Search ID 719080
PDQ Open Trial Search ID 719080 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C99228
Contributing_Source CTRP
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom